Telix Pharmaceuticals Announces Publication Of Results From The ProstACT SELECT Study In Cancers, A Peer-Reviewed Journal; Peer-Reviewed Publication of ProstACT SELECT1 Results Confirm The Utility Of 68Ga -PSMA-PET Imaging To Select Patients For TLX591-Tx Therapy Using A Theranostic Approach
Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.Consistent with previously reported
Telix's cancer study results got published in a trusted medical journal, showing their imaging test helps doctors pick the right patients for their treatment. This kind of proof from independent experts helps doctors and hospitals feel more confident about using the company's products.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.